WebMD Health News
Nov. 1, 2013 -- The cholesterol-lowering drug Crestor (rosuvastatin) was the nation's most prescribed drug in the past 12 months, according to a new report from research firm IMS Health. New "...
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse reactions reported in at least 2% and at a greater rate than placebo for patients treated with VASCEPA based on pooled data across two clinical studies are listed in Table 1.
Table 1: Adverse Reactions
Occurring at Incidence > 2% and Greater than Placebo in Double-Blind,
|*Studies included patients with triglycerides values of 200 to 2000 mg/dL.|
An additional adverse reaction from clinical studies was oropharyngeal pain.
Read the Vascepa (icosapent ethyl capsules) Side Effects Center for a complete guide to possible side effects
Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in those studies has not exceeded normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.
Drug Abuse And Dependence
VASCEPA does not have any known drug abuse or withdrawal effects.
Read the Vascepa Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 9/30/2015
Additional Vascepa Information
Report Problems to the Food and Drug Administration
Tips to keep it under control.